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Objectives: Access to large-scale public health claims databases is limited due 
to privacy concerns and lack of a unique identifier in Japan. Since such databases 
were not originally designed for outcomes research, we assessed the usefulness 
of one of the commercial databases in identifying treatment patterns in routine 
clinical practice. MethOds: Treatment patterns for patients with exudative age-
related macular degeneration (AMD) using anti-vascular endothelial growth factor 
(anti-VEGF) was selected as an example to enhance our understanding of real-
world clinical practice. A retrospective open-cohort study of patients diagnosed 
with AMD and treated from January 2010 to December 2012 at community hospitals 
employing Diagnostic Procedure Combination payment system was conducted by 
using hospital claims database provided by Medical Data Vision, Co., Ltd. Strengths 
and weaknesses of using the database were also identified. Results: During the 
study period, 248 patients were diagnosed with AMD and received ranibizumab, 
19 patients received pegaptanib, and two patients received aflibercept. Among the 
patients who received ranibizumab, the average number of ranibizumab injec-
tions per year was 3.21±2.38. The strength of the database was granularity of 
data including daily medication and medical procedural histories that allow us to 
obtain key parameters of analyzing treatment patterns. A major weakness was no 
unique identifier for patients; thus, a patient would be recorded as two different 
entries in the database if s/he visited two different hospitals. cOnclusiOns: 
The results show that the commercial hospital claims database was useful to 
understand treatment patterns of exudative AMD at non-university hospital set-
tings. Since treatment guidelines are usually written based on published clinical 
trial evidence, this type of database research provides an understanding of real 
life clinical practice and its associated patient outcomes, contributing to better 
adherence and future updates of treatment guidelines.
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Objectives: To compare official prices and refunding limits of the selected drugs 
with the prices and limits used in the manufacturers’ Budget Impact Analyses 
(BIAs) submitted in the reimbursement applications and in the manufactur-
ers’ documentations from request for removing, altering the level or method of 
financing of medicines to AHTAPol and to verify the accuracy of their assump-
tions. MethOds: Prices and limits proposed in BIAs in years 2007-2011 and 
official prices and limits for the same medicine were compared. Only BIAs for 
medicines which had been reimbursed for at least one year were included in 
the analysis. The official prices and limits were obtained from reimbursed drugs 
list published in Ministry of Health’s Orders. Results: In the studied period, 
72 drugs were included in the analysis. Among them, 51,39% (37/72) were from 
reimbursement applications and 48,61% (35/72) were from requests for remov-
ing, altering the level or method of financing of medicines, respectively. As 
a result, 13% (9/72) of the prices proposed in the BIAs were underestimated. 
Median and mean difference (MD) between official prices and prices used in 
BIAs for the same medicine were 95% and 91% respectively. The overestimation 
was found in 39% BIAs (28/72); median = 117%, MD = 124%. Rest of the prices 
were equal 49% (35/72). Limits were underestimated in 8% (6/72) of the BIAs. 
Median and mean difference between official prices and prices used in BIAs 
were 97% and 98% respectively. Overestimation of the limits was found in 57% 
(41/72) of the BIAs; median = 133%, MD = 117%. Rest of the limits were equal 35% 
(25/72). cOnclusiOns: Among the contradictory prices and limits official ones 
were higher than the prices assumed in BIAs for the same medicines. There is a 
strong need for further research.
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Objectives: Many public health decisions are made based on information con-
tained in medical publications. Therefore developing a publication strategy is a 
benefit for the pharmaceutical industry as it ensures an efficient dissemination of 
drug efficacy and safety evidence and an ethic development of the publications. In 
the context of outcome research, a publication strategy should take into considera-
tion specific aspects related to the field (e.g., dealing with local, regional and global 
levels) and is important to ensure that unbiased information is provided to medical 
decision makers on time for the good of public health. A literature review was con-
ducted to investigate if published guidelines on the development of a publication 
strategy in the context of outcome research exist. MethOds: A literature search 
of English articles was conducted on MEDLINE and Scopus. Search terms included 
“publication strategy” OR “publication planning” OR “publication coordination” 
AND “health economics” OR “health outcome” OR “outcome research” OR “medical 
economics”. Independent extraction of articles was performed using predefined 
data fields. Results: The search provided four citations; all were discarded after 
reviewing the abstracts. However, a simple search for the keywords “publication 
strategy” OR “publication planning” returned 85 hits in fields as various as psychol-
ogy, political science, environmental science and medicine. None of the citations 
was specific to outcome research. cOnclusiOns: The results of the literature 
search showed that the development of a publication strategy is an important 
concept through many different domains. However, no published guideline on 
the development of a publication strategy in the context of outcome research 
was found. A publication strategy specific to outcome research publications will 
be presented including recommendations regarding the key aspects that should 
be covered in an efficient outcome research publication strategy such as a criti-
cal assessment of published literature, identification of gaps, and development 
of a strategic plan.
patients, and were geographically diverse, representing populations in Europe, the 
USA, and Australia. Each recommended data source had unique strengths and limi-
tations for use in real-world evidence studies, and together they had the potential 
to provide consistent and complementary information. The study output provided 
a valuable tool for global and local investigators. cOnclusiOns: Observational 
data sources are diverse. A systematic understanding of real-world evidence can 
guide the development of a coherent strategy for designing observational studies 
to support clinical research.
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Objectives: To assess the feasibility of use of medical-transcription data for 
real-world clinical evidence generation in the US. MethOds: Majority of clini-
cal practices in the US are experimenting digitization of patient medical records 
for two reasons: patient-management/care-delivery and billing/administrative/
legal documentation purposes. Increasingly, physicians are using medical-tran-
scription services, where physicians dictate details of patient visits and send the 
voice-recording-device to medical-transcription organization which processes 
voice-data and delivers electronic-files back to clinics; physicians review/revise/
append the electronic-documentation and adds data to their patient-database-
repository for future use. This pilot study assessed the utility of de-identified med-
ical-transcription data in evaluating patient-physician dynamics and real-world 
treatment patterns/outcomes and documented adverse-events(AEs) using random 
set of adult SLE patients who initiated belimumab (a recently-launched biologic) 
within the past 2years as part of usual care. SLE was chosen specifically because of 
its complex clinical management issues. Results: Nineteen belimumab patient 
transcription-records (de-identified) were reviewed (mean age:39.4yrs; female:95%). 
Top-4 clinical-manifestations at belimumab-start were: musculoskeletal(68%)/
mucocutaneous(53%)/constitutional(42%)/renal(21%). Physicians discussed beli-
mumab-attributes (specifically, infection-risks/AEs/etc), asked patients to do their 
own research on belimumab, and cited insurance/reimbursement-issues prior to 
belimumab-start in 58%, 26% & 26% of cases respectively; 11% of patients asked for 
belimumab. Top-3 documented-reasons for belimumab-start were: steroid-spar-
ing(32%), control autoimmune diathesis(11%), control SLE-flares(16%). In 47% of 
patients, belimumab (at initiation) replaced another medication (majority:steroids/
immunosuppressants); concomitant SLE-medications were: antimalarials(84%)/
oral-steroids(68%)/Immunosuppressants(47%). Average belimumab-duration was 
8.1months (overall data availability/patient:23.8months). During the observation 
period, 42% had > = 1AE (e.g., diarrhea/rash/bronchiolitis/alopecia/upper-respira-
tory-track-infection), 42% discontinued belimumab (but 26% re-started) and 47% 
had some physician-documented improvement in outcomes (e.g., joint-pain/
rash/energy level/fatigue). One patient had documented steroid-stoppage post-
belimumab initiation. cOnclusiOns: Medical-transcription data may provide 
documented real-world evidence of treatment dynamics and clinical status/out-
comes associated with patient care. In this random cohort of SLE patients using 
belimumab, belimumab appears to provide some demonstrable benefits in almost 
half of the patients.
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Objectives: In 2002, PROQOLID was launched to provide an overview of existing 
PRO instruments and a facilitated access to the instruments and their develop-
ers through the structured presentation of synthesized, reliable, and constantly 
updated data. With the constant growth of electronic capture of patient-reported 
outcomes, detailing information about modes of data collection (i.e., paper vs. 
electronic) in PROQOLID might become a crucial step in updating the database. 
The objective of this study was: (1) To review how e-PROs are currently reported 
in PROQOLID; and (2) To propose (if needed) ways of clarifying and updating e-PRO 
information. MethOds: PROQOLID was searched to retrieve current information 
about e-PROs using an advanced search engine. Results: The e-PRO information 
was found under the category “mode of administration.” Three options could be 
chosen: computer-administered, electronic-administered, and IVR (Interactive Voice 
Response) version. Out of the 751 instruments in the database, 37 (5%) were reported 
with e-PRO information. Information about existing translations of electronic ver-
sions was clearly specified for three questionnaires. To clarify and update e-PRO 
information in PROQOLID, several recommendations are proposed: (1) To create 
a new category, i.e., mode of data collection, in order to differentiate it from the 
“mode of administration” category; (2) To categorize each mode of data collection 
into five subcategories [i.e., Hand-Held Device, IVR, Internet web-data capture, Pen, 
and Tablet]; and (3) To provide a list of all translations available in each mode of 
data collection. cOnclusiOns: This review has shown that PROQOLID already 
includes e-PRO information. Recommendations are given on how to modify the 
organization and content of the database to present the information on electronic 
capture of PROs.
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